יומירה 40 מ"ג

国: イスラエル

言語: ヘブライ語

ソース: Ministry of Health

有効成分:

ADALIMUMAB 40 MG / 0.8 ML

から入手可能:

ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL

ATCコード:

L04AA17

医薬品形態:

SOLUTION FOR INJECTION

構図:

PEN

投与経路:

S.C

製:

ABBVIE LTD, UK

治療群:

ADALIMUMAB

適応症:

* Rheumatoid arthritis: Humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray adn to impove physical function when given in combination with methotrexate. * Crohn's disease : Humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.Humira is indicated for reducing signs and symptoms and inducing clinical r

承認日:

2009-07-01